Loading
Latest filing published 16 Oct 2026 for 엘앤케이바이오. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
강국진 (chief executive) discloses dealings in 엘앤케이바이오 to DART (FSS). Over a trading history stretching from 1 April 2021 to 16 October 2026, the count stands at 36 filings.
On the market, this insider has only ever bought: 6 purchases. The totals do not cover 6 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2026 to date brings 6 purchases and no sales.
Across 4 purchases, this insider has always bought alone, with no colleague buying within 30 days.
The latest filing, published on 16 October 2026, reports a transaction in 엘앤케이바이오. The last purchase on record was published on 3 August 2026, which is 76 days ago. The median gap between a trade and its publication by DART (FSS) is 3 days. Until a filing is published, the market cannot know about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 36 declarations